Biomotion Sciences Warrant
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more
Biomotion Sciences Warrant (SLXNW) - Total Assets
Latest total assets as of September 2025: $11.61 Million USD
Based on the latest financial reports, Biomotion Sciences Warrant (SLXNW) holds total assets worth $11.61 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biomotion Sciences Warrant - Total Assets Trend (2020–2024)
This chart illustrates how Biomotion Sciences Warrant’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biomotion Sciences Warrant - Asset Composition Analysis
Current Asset Composition (December 2024)
Biomotion Sciences Warrant's total assets of $11.61 Million consist of 78.6% current assets and 21.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Biomotion Sciences Warrant's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomotion Sciences Warrant's current assets represent 78.6% of total assets in 2024, an increase from 40.0% in 2020.
- Cash Position: Cash and equivalents constituted 41.5% of total assets in 2024, up from 40.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomotion Sciences Warrant Competitors by Total Assets
Key competitors of Biomotion Sciences Warrant based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Biomotion Sciences Warrant - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biomotion Sciences Warrant generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biomotion Sciences Warrant is currently not profitable relative to its asset base.
Biomotion Sciences Warrant - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.97 | 0.85 | 1.76 |
| Quick Ratio | 3.97 | 0.85 | 1.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.27 Million | $ -536.00K | $ 22.30K |
Biomotion Sciences Warrant - Advanced Valuation Insights
This section examines the relationship between Biomotion Sciences Warrant's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -45.5% |
| Total Assets | $2.86 Million |
| Market Capitalization | $50.92K USD |
Valuation Analysis
Below Book Valuation: The market values Biomotion Sciences Warrant's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biomotion Sciences Warrant's assets decreased by 45.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomotion Sciences Warrant (2020–2024)
The table below shows the annual total assets of Biomotion Sciences Warrant from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.86 Million | -45.53% |
| 2023-12-31 | $5.26 Million | -43.68% |
| 2022-12-31 | $9.33 Million | -91.91% |
| 2021-12-31 | $115.41 Million | +89092.47% |
| 2020-12-31 | $129.40K | -- |